MCID: HYP020
MIFTS: 63

Hyperprolactinemia

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Reproductive diseases, Metabolic diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 57 12 76 75 37 29 55 6 44 15 73
Chiari-Frommel Syndrome 12 53 44 73
Hprl 57 75
Familial Isolated Prolactin Receptor Deficiency 59
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 59
Hyperprolactinaemia 12
Hyperprolactinemia, 40

Characteristics:

Orphanet epidemiological data:

59
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
hyperprolactinemia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 615555
Disease Ontology 12 DOID:12700
ICD10 33 E22.1
NCIt 50 C113168
Orphanet 59 ORPHA397685
ICD10 via Orphanet 34 E22.1
MedGen 42 C0020514
KEGG 37 H01388

Summaries for Hyperprolactinemia

OMIM : 57 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to mccune-albright syndrome and gigantism. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Jak-STAT signaling pathway. The drugs Dopamine and Cabergoline have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and ovary, and related phenotypes are menorrhagia and female hypogonadism

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

UniProtKB/Swiss-Prot : 75 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Wikipedia : 76 Hyperprolactinemia or hyperprolactinaemia is the presence of abnormally high levels of prolactin in the... more...

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 mccune-albright syndrome 31.6 GH1 IGF1 PRL SST
2 gigantism 30.9 GH1 PRL
3 hypogonadotropism 30.6 GNRH1 PRL
4 peripartum cardiomyopathy 30.5 DRD2 PRL
5 lymphocytic hypophysitis 30.3 GH1 POMC
6 galactorrhea 30.3 DRD2 IGF1 PRL PRLR
7 central precocious puberty 30.1 GNRH1 IGF1
8 tetrahydrobiopterin deficiency 30.1 GH1 PRL
9 non-functioning pituitary adenoma 30.0 GH1 SST
10 fasting hypoglycemia 29.9 IGF1 POMC
11 gynecomastia 29.9 POMC PRL SHBG
12 impotence 29.7 PRL SHBG VIP
13 premature ovarian failure 1 29.5 GNRH1 PRL SHBG
14 infertility 29.5 GNRH1 H19 PRL PRLR
15 polycystic ovary syndrome 29.4 GNRH1 IGF1 PRL SHBG
16 ovarian disease 29.4 GNRH1 IGF1 PRL SHBG
17 hypothalamic disease 29.3 GH1 GNRH1 POMC PRL
18 amenorrhea 29.3 GNRH1 POMC PRL SHBG TRH
19 anovulation 29.2 GNRH1 IGF1 PRL SHBG
20 precocious puberty 29.2 GH1 GNRH1
21 adenoma 29.2 GH1 IGF1 POMC PRL SST
22 fibrous dysplasia 29.2 GH1 IGF1 PRL SST
23 insulin-like growth factor i 29.1 GH1 IGF1 PRL SHBG
24 adrenal gland hyperfunction 29.0 GH1 POMC PRL SST
25 multiple endocrine neoplasia, type i 29.0 PRL SST VIP
26 bipolar disorder 29.0 DRD2 IGF1 PRL SHBG
27 hypopituitarism 29.0 GH1 GNRH1 IGF1 POMC PRL
28 chiasmal syndrome 29.0 GNRH1 POMC PRL SST
29 hypothyroidism 28.7 GH1 IGF1 POMC PRL SHBG TRH
30 empty sella syndrome 28.6 GH1 GNRH1 IGF1 POMC PRL TRH
31 hyperandrogenism 28.6 GNRH1 IGF1 POMC PRL SHBG
32 acromegaly 28.6 GH1 IGF1 POMC PRL SST TRH
33 pituitary tumors 28.5 GH1 IGF1 POMC PRL SST
34 hyperthyroidism 28.3 GH1 PRL SHBG SST TRH
35 functioning pituitary adenoma 28.0 DRD2 GH1 POMC PRL SST TRH
36 breast cancer 26.2 GNRH1 H19 IGF1 PRL PRLR PTHLH
37 amenorrhea-galactorrhea syndrome 11.4
38 ahumada del castillo syndrome 11.4
39 galactorrhoea-hyperprolactinaemia 11.1
40 fibrous dysplasia/mccune-albright syndrome 10.8 GH1 PRL
41 generalized resistance to thyroid hormone 10.8 PRL TRH
42 schizophreniform disorder 10.8 DRD2 PRL
43 social phobia 10.7 DRD2 PRL
44 sella turcica neoplasm 10.7 POMC PRL
45 tuberculum sellae meningioma 10.7 POMC PRL
46 suprasellar meningioma 10.7 POMC TRH
47 acth-secreting pituitary adenoma 10.7 POMC PRL
48 mammographic density 10.6 IGF1 PRL
49 isolated growth hormone deficiency, type ib 10.6 GH1 IGF1
50 postmenopausal atrophic vaginitis 10.5 PRLR SHBG

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Chest Breasts:
galactorrhea (in some patients)

Endocrine Features:
elevated prolactin levels


Clinical features from OMIM:

615555

Human phenotypes related to Hyperprolactinemia:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 menorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000132
2 female hypogonadism 59 32 occasional (7.5%) Occasional (29-5%) HP:0000134
3 amenorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0000141
4 infertility 59 32 occasional (7.5%) Frequent (79-30%) HP:0000789
5 oligomenorrhea 59 32 occasional (7.5%) Very frequent (99-80%) HP:0000876
6 osteopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000938
7 osteoporosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000939
8 hemorrhagic ovarian cyst 59 32 frequent (33%) Frequent (79-30%) HP:0012886
9 galactorrhea 59 32 occasional (7.5%) Very frequent (99-80%) HP:0100829
10 prolactin excess 32 HP:0000870

MGI Mouse Phenotypes related to Hyperprolactinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 PTHLH IGF1 SST POMC TRH DRD2
2 endocrine/exocrine gland MP:0005379 10.06 IGF1 PTHLH POMC TRH DRD2 PRL
3 immune system MP:0005387 9.92 PTHLH IGF1 SST POMC DRD2 PRL
4 adipose tissue MP:0005375 9.83 PTHLH IGF1 POMC DRD2 PRLR
5 integument MP:0010771 9.8 PTHLH IGF1 POMC DRD2 PRL GNRH1
6 neoplasm MP:0002006 9.63 IGF1 POMC DRD2 PRL GNRH1 PRLR
7 nervous system MP:0003631 9.61 PTHLH IGF1 SST POMC DRD2 PRL
8 reproductive system MP:0005389 9.17 PTHLH IGF1 DRD2 PRL GNRH1 PRLR

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Cabergoline Approved Phase 4,Not Applicable 81409-90-7 54746
3
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
4
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
5
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
7
Amantadine Approved Phase 4 768-94-5 2130
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
12 Serotonin 5-HT2 Receptor Antagonists Phase 4
13 Serotonin Agents Phase 4,Phase 3,Not Applicable
14 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Paliperidone Palmitate Phase 4
19 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
21 Dopamine D2 Receptor Antagonists Phase 4
22 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
26 Analgesics Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Estradiol 17 beta-cypionate Phase 4
29 Estradiol 3-benzoate Phase 4
30 Anti-Infective Agents Phase 4
31 Antiviral Agents Phase 4
32
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 50-67-9 5202
33
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
34
Calcium Carbonate Approved, Investigational Phase 3 471-34-1
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
36
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
37 Hormone Antagonists Phase 3,Phase 2
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
39 Quetiapine Fumarate Phase 3 111974-72-2
40 Micronutrients Phase 3
41 Gastrointestinal Agents Phase 3
42 Trace Elements Phase 3
43 Antacids Phase 3
44 Ergocalciferols Phase 3
45 Vitamins Phase 3
46 Anti-Ulcer Agents Phase 3
47 Bone Density Conservation Agents Phase 3
48 Calcium, Dietary Phase 3
49 Vitamin D2 Nutraceutical Phase 3
50 Calciferol Nutraceutical Phase 3

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
11 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
12 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3 Quetiapine XR;Risperidone
13 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2 PGD granules;Placebo
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
15 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
16 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
17 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232 Not Applicable Aripiprazole
18 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
19 TSH And AMH in Infertile Women Unknown status NCT02710175
20 Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Completed NCT03569787
21 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
22 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298 Not Applicable Aripiprazole;Placebo
23 Characterization of Macroprolactinemia Completed NCT00436111
24 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
25 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711 Study Drug
26 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
27 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
28 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
29 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
30 Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) Completed NCT01495741
31 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
32 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
33 Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors Completed NCT01568359
34 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
35 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
36 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
37 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Active, not recruiting NCT02092129
38 Pituitary Function and Spontaneous Intracranial Hypotension Active, not recruiting NCT02603549
39 Assessing Fertility Potential in Female Cancer Survivors Active, not recruiting NCT01143844
40 Long-term Antipsychotic Pediatric Safety Trial (LAPS) Not yet recruiting NCT03522168 Risperidone;Aripiprazole
41 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Withdrawn NCT00699530

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: chiari-frommel syndrome

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

# Genetic test Affiliating Genes
1 Hyperprolactinemia 29 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

41
Pituitary, Bone, Ovary, Testes, Endothelial, Thyroid, Prostate

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 809)
# Title Authors Year
1
Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns. ( 29896007 )
2018
2
Hyperprolactinemia as a Side Effect of Long-Acting Injectable Risperidone Therapy or a Symptom of Klinefelter Syndrome - a Diagnostic and Therapeutic Dilemma. ( 29546865 )
2018
3
Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. ( 29334291 )
2018
4
Metabolic Syndrome in Hyperprolactinemia. ( 29894997 )
2018
5
The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia. ( 29475005 )
2018
6
Frequency of Macroprolactin in Hyperprolactinemia. ( 29394965 )
2018
7
Dopamine agonist withdrawal in hyperprolactinemia: when and how. ( 29124662 )
2018
8
Primary Amenorrhea Associated with Hyperprolactinemia in Polyglandular Autoimmune Syndrome Type II: A Case Report. ( 29949817 )
2018
9
Interpretation of serum gonadotropin levels in hyperprolactinemia. ( 29660734 )
2018
10
Short-Term Hyperprolactinemia Reduces the Expression of Purinergic P2X7 Receptors during Allergic Inflammatory Response of the Lungs. ( 29874677 )
2018
11
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. ( 29778097 )
2018
12
Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. ( 29043560 )
2018
13
Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. ( 29768629 )
2018
14
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia. ( 29403128 )
2018
15
Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. ( 29241908 )
2017
16
Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. ( 28529200 )
2017
17
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach. ( 28440197 )
2017
18
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( 28372526 )
2017
19
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
20
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. ( 29112461 )
2017
21
Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on BIVAD. ( 27748657 )
2017
22
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
23
Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. ( 28236625 )
2017
24
Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. ( 28828544 )
2017
25
The central mechanism of risperidone-induced hyperprolactinemia. ( 28336493 )
2017
26
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( 28396166 )
2017
27
Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. ( 27773859 )
2017
28
Hyperprolactinemia with low dose of risperidone in a young female. ( 28558899 )
2017
29
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. ( 28235557 )
2017
30
Re: Myocardial Recovery in Peripartum Cardiomyopathy after Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28114195 )
2017
31
Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. ( 28259983 )
2017
32
Cabergoline for hyperprolactinemia: getting to the heart of it. ( 28260205 )
2017
33
An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? ( 28791188 )
2017
34
Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. ( 27671881 )
2017
35
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. ( 28437810 )
2017
36
Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. ( 28889207 )
2017
37
Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. ( 28925774 )
2017
38
The mechanism of selfheal extract in treating hyperprolactinemia. ( 28946556 )
2017
39
Reply to: Hyperprolactinemia and Hirsutism in Patients without Polycystic Ovary Syndrome. ( 28761266 )
2017
40
Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach. ( 28845595 )
2017
41
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27709470 )
2017
42
Re: Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28169846 )
2017
43
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia. ( 28320278 )
2017
44
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. ( 28775691 )
2017
45
Effects of TNF-I+ on penile structure alteration in rats with hyperprolactinemia. ( 28763467 )
2017
46
Pituitary gamma-aminobutyric acid receptor stimulation by carnitine may be a new strategy for antipsychotic-induced hyperprolactinemia. ( 28569425 )
2017
47
Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study. ( 29317896 )
2017
48
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
49
Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia. ( 28670538 )
2017
50
Antipsychotic-induced hyperprolactinemia in Tourette syndrome. ( 28740637 )
2017

Variations for Hyperprolactinemia

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

75
# Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

ClinVar genetic disease variations for Hyperprolactinemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh37 Chromosome 5, 35070276: 35070276
2 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh38 Chromosome 5, 35070174: 35070174

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to KEGG:

37
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 Jak-STAT signaling pathway hsa04630
3 Prolactin signaling pathway hsa04917

Pathways related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.54 DRD2 GH1 GNRH1 POMC PRL PRLR
2
Show member pathways
12.4 GH1 IGF1 PRL PRLR
3
Show member pathways
11.87 GH1 IGF1 POMC
4 11.71 POMC PTHLH VIP
5 11.62 GH1 IGF1 PRLR
6 11.14 GH1 IGF1 PTHLH
7
Show member pathways
10.93 POMC TRH
8
Show member pathways
10.74 GH1 PRL PRLR
9 10.51 GNRH1 SHBG

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 GH1 GNRH1 IGF1 POMC PRL PTHLH
2 extracellular region GO:0005576 9.36 GH1 GNRH1 IGF1 POMC PRL PRLR
3 endosome lumen GO:0031904 9.13 GH1 PRL PRLR

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.84 IGF1 PRL PTHLH VIP
2 G-protein coupled receptor signaling pathway GO:0007186 9.8 DRD2 GNRH1 POMC PTHLH SST TRH
3 negative regulation of cell proliferation GO:0008285 9.76 DRD2 GNRH1 PTHLH SST
4 response to ethanol GO:0045471 9.61 DRD2 GNRH1 TRH
5 female pregnancy GO:0007565 9.54 GNRH1 PRL PTHLH
6 adult walking behavior GO:0007628 9.52 DRD2 TRH
7 regulation of multicellular organism growth GO:0040014 9.51 IGF1 PRL
8 response to nutrient levels GO:0031667 9.5 GH1 IGF1 PRL
9 positive regulation of JAK-STAT cascade GO:0046427 9.49 GH1 PRL
10 positive regulation of receptor internalization GO:0002092 9.48 DRD2 GH1
11 cell-cell signaling GO:0007267 9.43 DRD2 GNRH1 POMC PTHLH SST TRH
12 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.4 GH1 IGF1
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.33 GH1 PRL PRLR
14 regulation of signaling receptor activity GO:0010469 9.28 GH1 GNRH1 IGF1 POMC PRL PTHLH

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.28 GH1 GNRH1 IGF1 POMC PRL PTHLH
2 neuropeptide hormone activity GO:0005184 9.16 POMC VIP
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....